-transparent.png){kind=logo}
A conjugate was developed between ricin A-chain and monoclonal antiallotypic antibody specific for L-chains of the rat Ig. Incubation of spleen cells with the conjugate (10(-7) M) resulted in a strong decrease of 1a-positive B-lymphocyte growth. At the same time spleen cells that lacked this antigen were not affected by immunotoxin (IT). Both the isolated antibodies and ricin A-chain did not inhibit cell growth in the same concentrations. IT injection to 10-day-old heterozygous rats (1a/1b) resulted in a partial suppression of Ig production with 1a-allotype. The conjugate was 4.5 times more effective than the isolated antibodies used to form it. The in vivo and in vitro differences in IT cytotoxicity were probably connected with insufficient efficacy of conjugate targeting in vivo.
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
August 1983,
Gan to kagaku ryoho. Cancer & chemotherapy,
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
July 1989,
Cancer research,
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
January 1985,
Molekuliarnaia biologiia,
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
December 1994,
Archives of pharmacal research,
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
October 1982,
Journal of the National Cancer Institute,
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
August 1984,
Journal of pharmacobio-dynamics,
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
July 1988,
Cancer research,
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
January 1987,
Cancer immunology, immunotherapy : CII,
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
December 1980,
Journal of immunology (Baltimore, Md. : 1950),
V A Rachmanova, and
A G Tonevitskiĭ, and
V V Cherapakhin, and
R A Bobreneva
October 1981,
Cancer research,
